3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Conditions
Prostatic Neoplasms
22
Prostatic Neoplasms, Castration-Resistant
6
Neoplasm Metastasis
4
Breast Neoplasms
3
Neoplasms
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer
2
Hormone Refractory Prostate Cancer
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Fractures, Bone
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Interventions
Ibandronic Acid
8
Zoledronic Acid
5
Irinotecan
3
Temozolomide
2
Radiation
2
Doxorubicin
2
Denosumab
2
Cyclophosphamide
2
Cryotherapy
2
Cryosurgery
2
selinexor
1
saracatinib
1
robatumumab
1
ridaforolimus
1
radium Ra 223 dichloride
1
pegfilgrastim
1
palbociclib
1
liposomal doxorubicin
1
cc-486
1
anlotinib
1
Vincristine
1
Topotecan
1
Taxes
1
Radiotherapy
1
Quality of Life
1
Pregabalin
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bone Neoplasms
×
radium Ra 223 dichloride
×
Clear all
NCT04681144
2023-10-26
QOLRAD
Bayer
Completed
103 enrolled